Construction and Validation of a Nomogram to Predict Overall Survival in Very Young Female Patients with Curatively Resected Breast Cancer

Figures & data

Figure 1 Flow diagram of patient selection.

Table 1 Patient Characteristics of the Training Cohort and the Validation Cohort

	Training Cohort (n=10,872)	Validation Cohort (n=1002)
Age
10–15	5	0
16–20	46 (0.4%)	2 (0.002%)
21–25	568 (6.8%)	56 (5.6%)
26–30	2653 (24.4%)	363 (36.2%)
31–35	7600 (69.9%)	577 (57.6%)
Race
White	7623 (70.1%)	0
Black	1666 (15.3%)	0
Asian or Pacific Islander	1427 (13.1%)	1002 (100%)
American Indian/Alaska Native	73 (0.7%)	0
Unknown	83 (0.8%)	0
Lateral
Right	5459 (50.2%)	485 (48.4%)
Left	5409 (49.8%)	511 (51.0%)
Both	0	6 (0.6)
Unknown	4	0
Histology (ICD-O-3)
Invasive carcinoma of NST	9848 (90.6%)	929 (92.7%)
Favorable	213 (2.0%)	40 (4.0%)
Metaplastic	62 (0.6%)	0
Others	749 (6.9%)	33 (3.3%)
Grade
I	718 (6.6%)	28 (2.8%)
II	3257 (30.0%)	443 (44.2%)
III	6220 (57.2%)	358 (35.7%)
IV	138 (1.3%)
Unknown	539 (5.0%)	173 (17.3%)
ER
Positive	6964 (64.1%)	685 (68.4%)
Negative	3550 (32.7%)	294 (29.3%)
Unknown	358 (3.3%)	23 (2.3%)
PR
Positive	5926 (54.5%)	646 (64.5%)
Negative	4520 (41.6%)	332 (33.1%)
Unknown	426 (3.9%)	24 (2.4%)
HER2
Positive	1513 (13.9%)	261 (26.0%)
Negative	4290 (39.5%)	648 (64.7%)
Unknown	5069 (46.6%)	93 (9.3%)
Stage, AJCC 6th
0	19 (0.2%)	2 (0.002%)
I	2931 (27.0%)	220 (22.0%)
II	5512 (50.7%)	507 (50.6%)
III	2410 (22.2%)	273 (27.2%)
T stage
Tis	19 (0.2%)	3 (0.03%)
1	4363 (40.1%)	329 (32.9%)
2	4780 (44.0%)	557 (55.6%)
3	1294 (11.9%)	77 (7.7%)
4	416 (3.8%)	36 (3.6%)
N stage
0	5564 (51.2%)	488 (48.7%)
1	3708 (34.1%)	279 (27.8%)
2	1027 (9.4%)	141 (14.1%)
3	573 (5.3%)	94 (9.4%)

Abbreviations: AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; NST, no special type; PR, progesterone receptor.

Figure 2 (A) Univariate and (B) multivariate analysis of overall survival for the training cohort.

Figure 3 Kaplan-Meier curves for overall survival stratified by (A) race, (B) grade, (C) T stage, and (D) N stage in the training cohort.

Figure 4 Nomograms predicting 3-, 5-, and 10-year overall survival for the training cohort.

Figure 5 Calibration plots of the nomogram for 3‐, 5‐, and 10-year overall survival (A–C) prediction in the training cohort, and 3‐, 5‐, and 10-year overall survival (D–F) prediction in the validation cohort.

Figure 6 Kaplan-Meier curves for overall survival stratified by risk groups based on total prognostic scores from the nomogram model for (A) the training cohort and (B) the validation cohort.